203 related articles for article (PubMed ID: 16885917)
1. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
Khan MA; Andrews S; Ismail-Khan R; Munster PN; Brem S; King J; Reintgen DS; Sondak VK; Daud AI
Cancer Control; 2006 Jul; 13(3):211-7. PubMed ID: 16885917
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
4. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
5. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S
Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
7. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract][Full Text] [Related]
10. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Tarhini AA; Kirkwood JM; Gooding WE; Cai C; Agarwala SS
J Clin Oncol; 2007 Sep; 25(25):3802-7. PubMed ID: 17761969
[TBL] [Abstract][Full Text] [Related]
11. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Weber RW; O'Day S; Rose M; Deck R; Ames P; Good J; Meyer J; Allen R; Trautvetter S; Timmerman M; Cruickshank S; Cook M; Gonzalez R; Spitler LE
J Clin Oncol; 2005 Dec; 23(35):8992-9000. PubMed ID: 16260693
[TBL] [Abstract][Full Text] [Related]
12. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Harting MS; Kim KB
Melanoma Res; 2004 Dec; 14(6):517-20. PubMed ID: 15577323
[TBL] [Abstract][Full Text] [Related]
13. Metastatic melanoma: a regional review and future directions.
Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
[TBL] [Abstract][Full Text] [Related]
14. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
O'Day SJ; Gammon G; Boasberg PD; Martin MA; Kristedja TS; Guo M; Stern S; Edwards S; Fournier P; Weisberg M; Cannon M; Fawzy NW; Johnson TD; Essner R; Foshag LJ; Morton DL
J Clin Oncol; 1999 Sep; 17(9):2752-61. PubMed ID: 10561350
[TBL] [Abstract][Full Text] [Related]
15. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
Flaherty LE
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
17. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of metastasized malignant melanoma].
Kamanabrou D
Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
[TBL] [Abstract][Full Text] [Related]
19. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Ron IG; Sarid D; Ryvo L; Sapir EE; Schneebaum S; Metser U; Asna N; Inbar MJ; Safra T
Melanoma Res; 2006 Feb; 16(1):65-9. PubMed ID: 16432458
[TBL] [Abstract][Full Text] [Related]
20. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]